Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Down 47.3% in August

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 19,643 shares, a decrease of 47.3% from the August 15th total of 37,252 shares. Currently, 2.3% of the shares of the company are sold short. Based on an average daily volume of 55,975 shares, the days-to-cover ratio is currently 0.4 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Galmed Pharmaceuticals Trading Down 0.9%

Shares of GLMD traded down $0.04 during mid-day trading on Thursday, hitting $4.59. 302,067 shares of the company traded hands, compared to its average volume of 52,894. The business has a 50-day moving average of $4.36 and a 200 day moving average of $4.71. The stock has a market capitalization of $4.78 million, a price-to-earnings ratio of -0.30 and a beta of 0.67. Galmed Pharmaceuticals has a one year low of $3.29 and a one year high of $13.20.

Galmed Pharmaceuticals (NASDAQ:GLMD) last released its earnings results on Wednesday, September 2nd. The biopharmaceutical company reported ($2.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.12) by $0.26.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.